S&S Healthcare Holding Ltd. AI Stock Analysis
S&S Healthcare Holding Ltd. (4198) AI Stock Analysis
S&S Healthcare Holding Ltd.
(TPEx:4198)
The score is constrained primarily by persistent operating losses, declining revenue, and negative cash flow. Reduced leverage and substantial equity provide financial support, but weak technical momentum and loss-based valuation keep the overall score near the bottom of the range.
S&S Healthcare Holding Ltd. (4198) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 1.08B
- Dividend Yield
- ―
- Average Volume (3M)
- 7,926
- Price to Earnings (P/E)
- -28.1
- Beta (1Y)
- 0.30
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- TW
- Employees
- 200
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Devices
S&S Healthcare Holding Ltd. Business Overview & Revenue Model
Company Description
S&S Healthcare Holding Ltd. is dedicated to the research, manufacturing, and global commercialization of medical imaging equipment. The company's operations extend across international markets, including significant presences in Taiwan, the United St...
S&S Healthcare Holding Ltd. Financial Statement Overview
Summary
Financial performance is weak overall: the income statement score is 18 due to declining revenue and widening losses, and the cash flow score is 25 because operating and free cash flow remain negative. The balance sheet score of 68 provides support through materially lower debt and improved leverage.
Income Statement
18Very NegativeBalance Sheet
68PositiveCash Flow
25Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 171.88M | 204.21M | 240.25M | 275.11M | 254.44M | 122.35M |
| Gross Profit | 53.22M | 58.85M | 75.01M | 35.66M | 38.39M | -7.93M |
| EBITDA | -28.59M | -27.02M | -17.60M | 133.81M | -33.61M | -71.64M |
| Net Income | -40.47M | -47.30M | -41.28M | 103.61M | -66.89M | -95.39M |
Balance Sheet | ||||||
| Total Assets | 353.99M | 377.06M | 433.83M | 613.34M | 531.06M | 294.12M |
| Cash, Cash Equivalents and Short-Term Investments | 73.47M | 122.39M | 150.02M | 198.99M | 112.32M | 121.88M |
| Total Debt | 25.38M | 28.44M | 53.32M | 88.08M | 183.91M | 124.06M |
| Total Liabilities | 101.62M | 100.37M | 116.24M | 209.24M | 315.64M | 199.92M |
| Stockholders Equity | 204.00M | 226.50M | 260.85M | 300.74M | 135.25M | 54.99M |
Cash Flow | ||||||
| Free Cash Flow | -39.80M | -29.12M | -71.10M | -99.25M | -142.07M | -80.36M |
| Operating Cash Flow | -34.83M | -26.66M | -52.04M | -68.10M | -72.91M | -70.52M |
| Investing Cash Flow | 15.62M | 12.33M | 7.22M | 181.95M | -82.25M | -9.25M |
| Financing Cash Flow | -14.14M | -33.66M | -4.56M | -29.59M | 149.97M | 112.47M |
S&S Healthcare Holding Ltd. Peers Comparison
Overall Rating
TW:624261Neutral
TW:410945Neutral
TW:412142Neutral
TW:419840Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 61Neutral | TWD 1.07B | 13.90 | ― | 5.97% | -0.93% | -10.65% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 45Neutral | TWD 1.21B | 256.25 | ― | 1.95% | 13.00% | 902.22% | |
| 42Neutral | TWD 1.01B | -25.02 | ― | ― | 0.08% | -10.61% | |
| 40Underperform | TWD 1.10B | -28.07 | ― | ― | ― | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4198 | S&S Healthcare Holding Ltd. | 48.00 | 10.00 | 26.32% | |
| TW:4109 | Jia Jie Biomedical Co., Ltd. | 10.25 | -5.51 | -34.96% | |
| TW:4121 | Rossmax International Ltd. | 12.25 | -3.05 | -19.93% | |
| TW:6242 | LI KANG BIOMEDICAL Co. Ltd. | 33.50 | -3.36 | -9.12% | |
| TW:6518 | Concord Medical Co Ltd | 29.85 | 4.98 | 20.00% | |
| TW:6543 | Perfect Medical Industry Co., Ltd. | 16.55 | -10.96 | -39.85% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026
